FOS and hepatocellular carcinoma: In a previous study of 150 human HCC samples, c-Fos expression was significantly higher in tumors than in non-tumor tissue (p<0.0001) [40], and elevated JNK1 (the c-Jun upstream activator) activity was identified in more than 50% of HCC samples relative to non-cancerous liver tissue [41].